| Brown, Cynthia J |
ELEVAATE, NCT05856331: Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema |
|
|
| Recruiting | 2 | 90 | Europe, US, RoW | INBRX-101, Zemaira | Inhibrx Biosciences, Inc | Alpha 1-Antitrypsin Deficiency, Emphysema | 05/25 | 06/25 | | |
NCT04798014: HERO-2: Home-Reported Outcomes With CFTR Modulator Therapy |
|
|
| Completed | N/A | 860 | US | | Indiana University, Folia Health, Cystic Fibrosis Foundation | Cystic Fibrosis | 08/23 | 08/23 | | |
| Recruiting | N/A | 146 | US | Parenthood | University of Pittsburgh, Cystic Fibrosis Foundation, National Heart, Lung, and Blood Institute (NHLBI) | Cystic Fibrosis, Parenthood Status | 02/30 | 02/31 | | |
| Contact, Use Central |
| Recruiting | 4 | 30 | US | IgPro10, Privigen | CSL Behring | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 12/29 | 12/29 | | |
NCT04167514: Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705) |
|
|
| Active, not recruiting | 3 | 136 | US | Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor (A1-P1), Placebo | CSL Behring, Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI) | Graft Versus Host Disease (GVHD) | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 126 | Europe, Japan, US, RoW | human immunoglobulin G, IgPro20, Hizentra, Placebo | CSL Behring, CSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406 | Dermatomyositis | 06/24 | 11/27 | | |
NCT05819775: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema |
|
|
| Recruiting | 3 | 20 | Europe, Canada, US, RoW | CSL312, Garadacimab | CSL Behring | Hereditary Angioedema (HAE) | 11/26 | 11/26 | | |
| Terminated | 3 | 194 | Europe, Canada, US, RoW | Clazakizumab, Physiologic saline solution | CSL Behring, ICON Clinical Research | Antibody-mediated Rejection | 04/24 | 04/24 | | |
NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs) |
|
|
| Recruiting | 3 | 35 | Canada, US, RoW | CSL222 (AAV5-hFIXco-Padua), Etranacogene dezaparvovec | CSL Behring | Hemophilia B | 10/28 | 10/28 | | |
MODULAATE, NCT03805789: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant |
|
|
| Recruiting | 2/3 | 310 | Europe, Japan, US, RoW | Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor, Placebo | CSL Behring | Acute-graft-versus-host Disease | 09/25 | 03/27 | | |
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis |
|
|
| Enrolling by invitation | 2/3 | 2310 | Europe, Canada, US, RoW | CSL300, Clazakizumab, Placebo | CSL Behring | Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease | 12/28 | 12/28 | | |
NCT01294020 / 2010-020925-42: Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf® |
|
|
| Active, not recruiting | 2 | 81 | Europe, RoW | Tacrolimus, Prograf, FK506, Tacrolimus prolonged release, FK506E, MR4, Advagraf, tacrolimus modified release, Astagraf XL, Graceptor, Prograf XL | Astellas Pharma Europe Ltd. | Intestine Transplantation, Kidney Transplantation, Lung Transplantation, Liver Transplantation, Heart Transplantation | 10/15 | 05/26 | | |
STARBORN-1, NCT05871970: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age |
|
|
| Recruiting | 2 | 38 | US | TARA-002 | Protara Therapeutics | Lymphatic Malformation | 12/25 | 05/26 | | |
ADVANCED-2, NCT05951179: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 127 | US, RoW | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 05/30 | 08/30 | | |
NCT04446000: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects |
|
|
| Terminated | 1 | 52 | Europe | CSL730, Recombinant trivalent human IgG1 Fc multimer, Placebo | CSL Behring | Immune Complex-mediated Autoimmune Diseases | 03/23 | 03/23 | | |
NCT05653713: Effects of CSL324 in the Lung After Segmental Challenge |
|
|
| Completed | 1 | 40 | Europe | CSL324, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody (mAb), Placebo | CSL Behring | Healthy Volunteers | 07/23 | 07/23 | | |
NCT04082754: A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers |
|
|
| Completed | 1 | 78 | Europe | Human beta common receptor antagonist monoclonal antibody, CSL311, Placebo | CSL Behring | Asthma | 11/23 | 11/23 | | |
ADVANCED-1, NCT05085990: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 1 | 12 | US | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 06/24 | 08/24 | | |
ADVANCED-1, NCT05085977: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) |
|
|
| Recruiting | 1 | 18 | Europe, US, RoW | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 06/24 | 07/24 | | |
NCT05937581: First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects |
|
|
| Recruiting | 1 | 60 | RoW | CSL040, Placebo | CSL Behring | Complement Deficiencies | 03/25 | 03/25 | | |
| Completed | N/A | 80 | Europe, US | | Protara Therapeutics | Intestinal Failure-associated Liver Disease | 06/23 | 06/23 | | |
IX-TEND 4001, NCT06008938: An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B |
|
|
| Recruiting | N/A | 500 | US | HEMGENIX, Etranacogene dezaparvovec, Factor IX (FIX) | CSL Behring | Hemophilia B | 08/43 | 08/43 | | |
| Singh, David |
| Active, not recruiting | 1 | 117 | Europe | KN-002 | Kinaset Therapeutics Inc | Asthma COPD | 12/23 | 04/24 | | |
| Recruiting | N/A | 100 | Canada, US, RoW | Invasive Electrophysiology Study | Western University, Canada, Canadian Institutes of Health Research (CIHR) | Sudden Cardiac Death | 03/23 | 05/23 | | |
NCT04088071: Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation |
|
|
| Recruiting | N/A | 15000 | US | Catheter ablation | Heart Rhythm Clinical and Research Solutions, LLC, Biosense Webster, Inc. | Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation | 12/27 | 12/27 | | |
| Singh, Dave |
TRECOS, NCT06264674: Comparison Between CHF5993 pMDI 200/6/12,5mg HFA-152a VS CHF5993 pMDI 200/6/12,5mg HFA-134a in Subjects With Asthma (Trecos) |
|
|
| Recruiting | 3 | 790 | Europe | CHF5993 200/6/12.5 μg pMDI HFA-152a, HFA-152a propellant, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a, HFA-134a propellant | Chiesi Farmaceutici S.p.A. | Asthma | 08/24 | 09/25 | | |
| Completed | 2 | 337 | Europe, Canada, US, RoW | Tezepelumab, Placebo | AstraZeneca, Amgen | Chronic Obstructive Pulmonary Disease (COPD) | 11/23 | 01/24 | | |
|
NCT06166056: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis |
|
|
| Recruiting | 1/2 | 45 | Europe | CHF6333, CHF6333 Placebo | Chiesi Farmaceutici S.p.A. | Bronchiectasis | 06/25 | 06/25 | | |
NCT04769869: A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma |
|
|
| Completed | 1 | 110 | Europe | AZD4604 for inhalation via DPI, Placebo for AZD4604 for inhalation via DPI, AZD4604 for IV administration, AZD4604 for oral administration | AstraZeneca | Asthma | 01/23 | 01/23 | | |
NCT05195008: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants |
|
|
| Completed | 1 | 72 | Europe | BIIB113, BIIB113-Matching Placebo, 11^C]BIO-1819578 | Biogen | Healthy Volunteer | 07/23 | 07/23 | | |
| Recruiting | 1 | 120 | Europe | SPYVAC01 | SpyBiotech Limited | Cytomegalovirus Infections | 04/25 | 04/25 | | |
NCT05965089: A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis. |
|
|
| Recruiting | 1 | 58 | Europe | Placebo, AX-202 | Arxx Therapeutics | Healthy Volunteers, Mild to Moderate Psoriasis | 07/24 | 07/24 | | |
| Wiesel, Philippe |
NCT05843578: STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease |
|
|
| Recruiting | 2 | 90 | Europe, Canada, US | AGMB-129, Placebo | Agomab Spain S.L. | Fibrostenotic Crohn's Disease | 12/25 | 12/25 | | |
NCT05937386: Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants |
|
|
| Completed | 1 | 14 | Europe | AGMB-129, MDZ | Agomab Spain S.L. | Healthy Volunteers | 09/23 | 09/23 | | |
NCT06181370: Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF |
|
|
| Recruiting | 1 | 76 | Europe | AGMB-447, placebo | Agomab Spain S.L. | IPF | 03/25 | 03/25 | | |
NCT06397508: Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants |
|
|
| Completed | 1 | 25 | Europe | AGMB-129 | Agomab Spain S.L. | Healthy Volunteers | 05/24 | 05/24 | | |
| Dilling, Daniel |
| Active, not recruiting | 3 | 160 | Europe, Canada, Japan, US, RoW | Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo | Savara Inc., Savara ApS, | Autoimmune Pulmonary Alveolar Proteinosis | 06/24 | 06/25 | | |
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 576 | Canada, US | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 06/25 | 06/25 | | |
|
|
MILED, NCT03150914: Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial |
|
|
| Recruiting | 3 | 60 | US | Sirolimus, Rapamycin | University of Cincinnati, National Heart, Lung, and Blood Institute (NHLBI), National Center for Advancing Translational Sciences (NCATS), The LAM Foundation | LAM, Lymphangioleiomyomatosis | 06/25 | 06/25 | | |
| Active, not recruiting | 3 | 202 | US | N-acetyl cysteine, NAC, Placebo | Weill Medical College of Cornell University, University of Virginia, University of Michigan, Pulmonary Fibrosis Foundation, University of Washington, National Heart, Lung, and Blood Institute (NHLBI), Three Lakes Foundation | Idiopathic Pulmonary Fibrosis | 12/25 | 12/25 | | |
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 698 | Canada, US | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Progressive Pulmonary Fibrosis, Interstitial Lung Disease | 11/27 | 11/27 | | |
IPF COMFORT, NCT05185089: Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis |
|
|
| Completed | 2 | 80 | Europe, US | Orvepitant Maleate, Placebo | Nerre Therapeutics Ltd., Pharm-Olam International | Cough, Idiopathic Pulmonary Fibrosis | 06/24 | 06/24 | | |
ELEVAATE, NCT05856331: Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema |
|
|
| Recruiting | 2 | 90 | Europe, US, RoW | INBRX-101, Zemaira | Inhibrx Biosciences, Inc | Alpha 1-Antitrypsin Deficiency, Emphysema | 05/25 | 06/25 | | |
NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF |
|
|
| Recruiting | 2 | 120 | Europe, US, RoW | BBT-877, Placebo | Bridge Biotherapeutics, Inc. | Idiopathic Pulmonary Fibrosis | 11/24 | 12/24 | | |
|
|
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 100 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 03/25 | | |
| Recruiting | N/A | 500 | US | | CareDx | Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection | 12/28 | 12/28 | | |
IPF-PRO, NCT01915511: Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry |
|
|
| Recruiting | N/A | 2000 | US | | Duke University, Boehringer Ingelheim | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 01/28 | 01/28 | | |
|
| Brickman, Chaim M |
NCT05653479: Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults |
|
|
| Completed | 1 | 32 | Europe | UPB-101, Formerly ASP7266 | Upstream Bio Inc. | Healthy | 04/23 | 05/23 | | |
NCT05448651: Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics |
|
|
| Completed | 1 | 32 | Europe | UPB-101, Formerly ASP7266, Placebo, 0.9% saline solution | Upstream Bio Inc. | Asthma | 08/23 | 10/23 | | |
| |
| Active, not recruiting | 3 | 290 | Europe | Metformin Hydrochloride, Placebo Oral Tablet | Universiteit Antwerpen, University Hospital, Antwerp | Chronic Kidney Diseases | 12/24 | 12/24 | | |
| Recruiting | 2 | 200 | Europe | Pentaglobin®/Standard of Care | RWTH Aachen University, Biotest | Peritonitis, Sepsis, Septic Shock | 09/27 | 03/28 | | |
| Chaudhuri, Nazia |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
IPF COMFORT, NCT05185089: Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis |
|
|
| Completed | 2 | 80 | Europe, US | Orvepitant Maleate, Placebo | Nerre Therapeutics Ltd., Pharm-Olam International | Cough, Idiopathic Pulmonary Fibrosis | 06/24 | 06/24 | | |
| Recruiting | N/A | 250 | Europe | Optional Bronchoscopy, Quality of Life Questionnaires, Blood Samples for Biomarkers, Home Hand Held Spirometry | University of Nottingham, Nottingham University Hospitals NHS Trust | Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis | 11/22 | 11/22 | | |
| Goldklang, Monica |
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein |
|
|
| Recruiting | 3 | 160 | Europe, Canada, US, RoW | Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride | Takeda, Takeda Development Center Americas, Inc. | Alpha1-Antitrypsin Deficiency | 03/27 | 03/29 | | |
ELEVAATE, NCT05856331: Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema |
|
|
| Recruiting | 2 | 90 | Europe, US, RoW | INBRX-101, Zemaira | Inhibrx Biosciences, Inc | Alpha 1-Antitrypsin Deficiency, Emphysema | 05/25 | 06/25 | | |
NCT03823443: COPD Exacerbation Blood and Urine Biomarkers Study |
|
|
| Terminated | N/A | 7 | US | | Columbia University, Alpha-1 Foundation | Chronic Obstructive Pulmonary Disease, Acute Exacerbation Copd, Alpha-1 Anti-trypsin Deficiency | 08/19 | 01/21 | | |
A1BC, NCT05297812: Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease |
|
|
| Active, not recruiting | N/A | 286 | US | | Columbia University, National Heart, Lung, and Blood Institute (NHLBI), Alpha-1 Foundation | Alpha 1-Antitrypsin Deficiency, Genetic Disease | 01/27 | 01/27 | | |
| Khan, Naimat |
ELEVAATE, NCT05856331: Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema |
|
|
| Recruiting | 2 | 90 | Europe, US, RoW | INBRX-101, Zemaira | Inhibrx Biosciences, Inc | Alpha 1-Antitrypsin Deficiency, Emphysema | 05/25 | 06/25 | | |
NCT05332704: Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685 |
|
|
| Suspended | 1 | 74 | Europe, RoW | ONO-4685, Placebo | Ono Pharmaceutical Co. Ltd | Plaque Psoriasis | 10/24 | 12/25 | | |
| MEU |
NCT06166056: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis |
|
|
| Recruiting | 1/2 | 45 | Europe | CHF6333, CHF6333 Placebo | Chiesi Farmaceutici S.p.A. | Bronchiectasis | 06/25 | 06/25 | | |
| Office, Recruitment and Eligibility |
NCT05246670: PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy |
|
|
| Active, not recruiting | 2 | 88 | US | Palmidrol, N-Palmitoyl Ethanolamide, N-Palmitoylethanolamide, OptiPEA, Palmitoyl Ethanolamide, Palmitoylethanolamide, PEA, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment | Academic and Community Cancer Research United, National Cancer Institute (NCI) | Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | 08/24 | 02/25 | | |
| Recruiting | 1/2 | 199 | Europe, Canada, US | Ziftomenib | Kura Oncology, Inc. | Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia | 09/24 | 09/25 | | |
REVERT, NCT05384119: Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer |
|
|
| Completed | 1/2 | 6 | US | TTI-101, Palbociclib, Ibrance ®, Aromatase inhibitor (AI), fulvestrant, ribociclib | Tvardi Therapeutics, Incorporated | Breast Cancer | 04/24 | 04/24 | | |
NCT05448651: Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics |
|
|
| Completed | 1 | 32 | Europe | UPB-101, Formerly ASP7266, Placebo, 0.9% saline solution | Upstream Bio Inc. | Asthma | 08/23 | 10/23 | | |
| Completed | N/A | 20 | US | | Rockefeller University | Racism, Stress, Psychological | 04/23 | 04/23 | | |
NCT06146218: Compassion-Based Resiliency Training (CBRT) Intervention on Racism-based Stress |
|
|
| Recruiting | N/A | 20 | US | Contemplative-Based Resilience Training (CBRT) | Rockefeller University | Racism, Stress, Psychological | 05/24 | 05/24 | | |
| Singh, ssor Dave |
NCT05448651: Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics |
|
|
| Completed | 1 | 32 | Europe | UPB-101, Formerly ASP7266, Placebo, 0.9% saline solution | Upstream Bio Inc. | Asthma | 08/23 | 10/23 | | |
| Rivera-Ortega, Pilar |
| Completed | 2 | 52 | Europe, RoW | C21 | Vicore Pharma AB, Orphan Reach | Idiopathic Pulmonary Fibrosis | 03/24 | 03/24 | | |
|
|
|
| Corral, Josie |
ELEVAATE, NCT05856331: Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema |
|
|
| Recruiting | 2 | 90 | Europe, US, RoW | INBRX-101, Zemaira | Inhibrx Biosciences, Inc | Alpha 1-Antitrypsin Deficiency, Emphysema | 05/25 | 06/25 | | |
| Traux, Brendon |
ELEVAATE, NCT05856331: Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema |
|
|
| Recruiting | 2 | 90 | Europe, US, RoW | INBRX-101, Zemaira | Inhibrx Biosciences, Inc | Alpha 1-Antitrypsin Deficiency, Emphysema | 05/25 | 06/25 | | |
